These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 5704795)

  • 21. Experimental study of peripheral circulation and bone growth. An experimental method for the quantitative determination of bone blood flow. 3.
    Ray RD; Kawabata M; Galante J
    Clin Orthop Relat Res; 1967; 54():175-85. PubMed ID: 5589601
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of strontium and magnesium on blood calcium].
    Pérez-Gallardo L; Córdova A
    Rev Esp Fisiol; 1991 Dec; 47(4):231-5. PubMed ID: 1812546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
    J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letter: Calcium-calcium exchange and calcium-strontium exchange in red cell ghosts.
    Olson EJ
    J Membr Biol; 1973 Nov; 13(4):411-2. PubMed ID: 4775519
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of intravenous phosphate on serum strontium and calcium.
    Eisenberg E
    N Engl J Med; 1970 Apr; 282(16):889-92. PubMed ID: 5434935
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of decreasing dialysate magnesium in patients with chronic renal failure.
    Burnell JM; Teubner E
    Proc Clin Dial Transplant Forum; 1976 Nov 19-22; 6():191-8. PubMed ID: 1029885
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased bone strontium levels in hemodialysis patients with osteomalacia.
    D'Haese PC; Schrooten I; Goodman WG; Cabrera WE; Lamberts LV; Elseviers MM; Couttenye MM; De Broe ME
    Kidney Int; 2000 Mar; 57(3):1107-14. PubMed ID: 10720963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative ultrafiltration of calcium and strontium in serum.
    SAMACHSON J; LEDERER H
    Proc Soc Exp Biol Med; 1958; 98(4):867-70. PubMed ID: 13591369
    [No Abstract]   [Full Text] [Related]  

  • 30. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.
    Kausz AT; Antonsen JE; Hercz G; Pei Y; Weiss NS; Emerson S; Sherrard DJ
    Am J Kidney Dis; 1999 Oct; 34(4):688-93. PubMed ID: 10516350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis.
    Raggi P; Giachelli C; Bellasi A
    Nat Clin Pract Cardiovasc Med; 2007 Jan; 4(1):26-33. PubMed ID: 17180147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of strontium on bone metabolism in hemodialysis patients].
    Gerstenfeld S; Hinojosa L; Serrano Arias M; Menéndez Rodríguez P; Fernández Martín JL; Marchante JM; García Alonso JI; Sanz-Medel A; Cannata Andía JB
    Nefrologia; 2003; 23 Suppl 2():52-6. PubMed ID: 12778855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A controlled evaluation of clinical and metabolic effects of dialysate calcium levels during regular hemodialysis.
    Mirahmadi KS; Duffy BS; Shinaberger JH; Jowsey J; Massry SG; Coburn JW
    Trans Am Soc Artif Intern Organs; 1971; 17():118-24. PubMed ID: 5158077
    [No Abstract]   [Full Text] [Related]  

  • 34. Increased serum strontium levels in dialysis patients: an epidemiological survey.
    Schrooten I; Elseviers MM; Lamberts LV; De Broe ME; D'Haese PC
    Kidney Int; 1999 Nov; 56(5):1886-92. PubMed ID: 10571798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic bone disease in chronic renal failure. I. Dialyzed uremics.
    Huffer WE; Kuzela D; Popovtzer MM
    Am J Pathol; 1975 Mar; 78(3):365-84. PubMed ID: 1119535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism and epidemiology of bone effects of cadmium.
    Kjellström T
    IARC Sci Publ; 1992; (118):301-10. PubMed ID: 1303956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of phosphate on serum strontium.
    Chaudhuri TK; Peterson RE; Christie JH
    Proc Soc Exp Biol Med; 1971 May; 137(1):1-4. PubMed ID: 5581661
    [No Abstract]   [Full Text] [Related]  

  • 39. Bisphosphonates in the renal patient.
    Cunningham J
    Nephrol Dial Transplant; 2007 Jun; 22(6):1505-7. PubMed ID: 17526921
    [No Abstract]   [Full Text] [Related]  

  • 40. Bone mineral content in chronic renal failure and after renal transplantation.
    Dalén N; Alvestrand A
    Clin Nephrol; 1973; 1(6):338-46. PubMed ID: 4594997
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.